Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844631 | 0.81 | RECQL (0.83) | RECQLALDH1A1HTTTSHRKDM4E | |
| SCHEMBL10366120 | 0.79 | ALDH1A1 (0.84) | RECQLALDH1A1HTTTSHRKDM4E | |
| SCHEMBL9975827 | 0.78 | ALDH1A1 (0.70) | RECQLALDH1A1HTTTSHRKDM4E | |
| SCHEMBL15807121 | 0.78 | RECQL (0.76) | RECQLALDH1A1HTTTSHRKDM4E | |
| SCHEMBL9975826 | 0.76 | RECQL (0.73) | RECQLALDH1A1HTTTSHRKDM4E | |
| SCHEMBL4477888 | 0.76 | RECQL (0.73) | RECQLALDH1A1HTTTSHRKDM4E | |
| SCHEMBL259219 | 0.76 | RECQL (0.73) | RECQLALDH1A1HTTTSHRKDM4E | |
| SCHEMBL1464710 | 0.76 | RECQL (0.73) | RECQLALDH1A1HTTTSHRKDM4E | |
| SCHEMBL15865967 | 0.74 | KDM4E (0.76) | RECQLALDH1A1HTTTSHRKDM4E | |
| SCHEMBL12776201 | 0.73 | RECQL (0.69) | RECQLALDH1A1HTTTSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | COCRYSTAL PHARMA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9707215-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL, DISCOVERY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | RECQL 123/4885ALDH1A1 577/4885HTT 4482/4885 |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2E, POLR2H, GTF3C3 | RECQL 146/4885ALDH1A1 743/4885HTT 4635/4885 |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | POLR2E, POLR2H, GTF3C3 | RECQL 146/4885ALDH1A1 743/4885HTT 4635/4885 |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | RECQL 123/4885ALDH1A1 577/4885HTT 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.